Company

SOLIGENIX, INC. (SNGX)

Standardized SEC financial data for SOLIGENIX, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000812796 · NASDAQ · Pharmaceutical Preparations.

Revenue growth (YoY)

-85.8%

Return on equity

-209.4%

Free cash flow

-$10.3M

Debt / equity

0.00×

Current ratio

2.39×

EPS (diluted)

$-2.14

Ratios for fiscal year 2024, standardized from SEC filings.

Income statement

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$2.4M	$824K	$949K	$839K	$119K	—
Cost of revenue	$1.8M	$729K	$551K	$742K	$119K	—
Gross profit	$538K	$96K	$398K	$97K

Balance sheet

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$18.7M	$26.0M	$13.4M	$8.4M	$7.8M	$7.9M
Total current assets	$19.5M	$26.6M	$13.9M	$9.5M	$8.8M	$8.8M
Property, plant & equipment	$24K	$22K	$18K	$12K

Cash flow

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$11.5M	-$11.7M	-$12.6M	-$8.6M	-$8.4M	-$10.3M
Capital expenditures	—	—	—	—	—	$6K
Free cash flow	—	—	—	—	—

Get SNGX data via API

# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/SNGX/financials \
  -H "X-API-Key: YOUR_KEY"

# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/SNGX/income-statement?format=csv" \
  -H "X-API-Key: YOUR_KEY"

Get a free API key Use with Claude (MCP) →View SNGX filings on SEC EDGAR →